ArticleCureus2026
Desmoglein-2 F833C Is Predicted to Disrupt Hydrophobic Interactions With the Armadillo Repeat Region 1 of Plakoglobin.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Desmoglein-2 (DSG2) is a desmosomal cadherin involved in cell-cell adhesion within cardiac tissue. A variant of uncertain significance (VUS), involving a phenylalanine-to-cysteine substitution at residue 833 (F833C), was identified and analyzed for its potential impact on the interaction between DSG2 and its intracellular binding partner plakoglobin. Molecular dynamics (MD) simulations, in silico pathogenicity predictions, and structural stability analyses were performed to assess the effects of this substitution. The F833C variant shows significantly reduced binding energy between DSG2 and plakoglobin, along with increased local structural flexibility measured by root mean square fluctuation (RMSF) at the mutation site and surrounding interaction interface. Notably, these local effects were observed despite apparent preservation of the overall global structure of the complex, which may indicate that the pathogenic effect of F833C predominantly involves local destabilization of the binding interface rather than gross conformational change. Structural analysis predicted that the phenylalanine-to-cysteine substitution disrupts hydrophobic interactions between DSG2 and plakoglobin's armadillo repeat region 1, potentially weakening desmosomal stability. Collectively, these findings suggest that the F833C variant may impair DSG2-plakoglobin interactions, supporting its potential contribution to arrhythmogenic right ventricular cardiomyopathy and warranting further experimental investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.